Subject: (Copy) NIH GUIDE - Vol. 19, No. 18, May 4, 1990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Wed, 02 May 90 14:51 EST

Good Afternoon Paul,
   This is the latest NIH Guide.  Please post to the NIH Listserver as:
    NIHGUIDE.050490
 Thanks.  Have a nice evening.
                              Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 10 pages (800 lines)
X-comment: RFAs described:  RR-90-02, CA-90-15, MH-90-20

     

     
NIH GUIDE - Vol. 19, No. 18, May 4, 1990

                                   NOTICES

NIH REGIONAL WORKSHOP ON IMPLEMENTATION OF THE PHS POLICY ON HUMANE
CARE AND USE OF LABORATORY ANIMALS ......................(84/128)............ 1
National Institutes of Health
Index:  NATIONAL INSTITUTES OF HEALTH

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

DEVELOPING AND IMPROVING INSTITUTIONAL ANIMAL RESOURCES (RFA RR-90-02) ...... 1
National Center for Research Resources               134/236, 804/1406)
Index:  RESEARCH RESOURCES

MECHANISMS OF VIRAL INDUCED AIDS-ASSOCIATED NEOPLASIA (RFA CA-90-15) ........ 3
National Cancer Institute                            (241/361, 1409/1757)
Index:  CANCER

                        ONGOING PROGRAM ANNOUNCEMENTS

SPECIAL EMPHASIS RESEARCH CAREER AWARD:  REHABILITATION AND AGING:
BIOMEDICAL AND PSYCHOSOCIAL PERSPECTIVES (PA-90-08) ....(367/545)............ 4
National Institute on Aging
Index:  AGING

EPIDEMIOLOGIC STUDIES OF CANCER AND HUMAN RETROVIRUSES (PA-90-09) ........... 7
National Cancer Institute                               (561/768)
Index:  CANCER

                                    ERRATA

RESEARCH DEMONSTRATIONS ON EMERGENCY MENTAL HEALTH SERVICES FOR
CHILDREN AND ADOLESCENTS (RFA MH-90-20) ................(774/786)............ 9
National Institute for Mental Health
Index:  MENTAL HEALTH

     

     
     
NOTE:  The NIH Guide for Grants and Contracts will not be published on
May 11.  The next issue will be May 18.

     

     

     

     

     

     
     
                                   NOTICES

NIH REGIONAL WORKSHOP ON IMPLEMENTATION OF THE PHS POLICY ON HUMANE CARE AND
USE OF LABORATORY ANIMALS
     
P.T. 42; K.W. 0201011, 1014002
     
National Institutes of Health
     
Reproposal of Part 3, Subparts A and D of the U. S. Department of
Agriculture's Animal and Plant Health Inspection Service (APHIS) Animal
Welfare Regulations is scheduled for the summer of 1990.  Subpart A (dogs and
cats) includes standards for the exercise of dogs and Subpart D (primates)
includes standards for a "physical environment adequate to promote the
psychological well-being of nonhuman primates."  The Public Health Service
(PHS) Policy requires compliance with the APHIS regulations.
     
The National Institutes of Health, Office for Protection from Research Risks,
is cosponsoring with the University of California, Los Angeles, on September 9
- 11, at the Lake Arrowhead Conference Center, an animal welfare education
program which will focus on institutional programs and procedures to meet the
reproposed APHIS requirements for dogs, cats and nonhuman primates.
     
The workshop is open to institutional administrators, members of animal care
and use committees, laboratory animal veterinarians, investigators and other
institutional staff who have responsibility for high-quality management of
sound institutional animal care and use programs.
     
For further information contact:
     
Ms. Gitta Walton
Director, Human Subjects and Animal Research Policy
6-956 Factor Building
University of California, Los Angeles
Los Angeles, CA  90024-1694
Telephone:  (213) 825-8714
     
For information concerning future workshops, contact:
     
Mrs. Roberta Sonneborn
Executive Asst. for Animal Welfare Education
Office for Protection from Research Risks
National Institutes of Health
Building 31, Room 5B59
9000 Rockville Pike
Bethesda, MD  20892
Telephone:  (301) 496-7163

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

DEVELOPING AND IMPROVING INSTITUTIONAL ANIMAL RESOURCES
     
RFA AVAILABLE:  RR-90-02
     
P.T. 34; K.W. 0780000, 1002002, 0720005
     
National Center for Research Resources
     
Application Receipt Date:  August 6, 1990
     
INTRODUCTION
     
The Animal Resources Program (ARP) of the National Center for Research
Resources (NCRR), National Institutes of Health (NIH), assists institutions in
developing and improving animal resources for biomedical research and research
training through the award of research and resource grants.  This document
relates to institutional animal resource improvement projects.  These projects
will be supported with funds anticipated to be made available to the
Department of Health and Human Services (DHHS) in Fiscal Year 1991 for this
activity.
     
A separate announcement and RFA will be issued later in calendar year 1990 for
a program related to animal facility improvement support for small research
institutions receiving less than $500,000 of Public Health Service support for
projects involving the use of animals.
     
              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 1
RESEARCH GOALS AND SCOPE
     
Animal resource improvement grants are awarded to assist biomedical research
and educational institutions in upgrading their animal facilities and in
developing administratively centralized programs of animal care.  Another
major objective is to enable institutions to comply with the USDA Animal
Welfare Act and DHHS policies related to the care and use of laboratory
animals.  Requests should describe a discrete project.  If this project is
part of a larger renovation plan, the larger plan can be described in the body
of the grant.  Requests are limited to alterations and renovations (A&R) to
improve laboratory animal facilities and major resource equipment related to
the improvement.  Both the need for resource improvements and a sound plan to
bring the entire animal resource up to required standards must be
demonstrated.
     
SUPPORT AND ELIGIBILITY
     
NCRR anticipates that $9.4 million may be available to support animal resource
improvement grants in Fiscal Year 1991.  It is anticipated that approximately
40 grant awards will be made.  The number and specific amounts of these awards
will depend on the merit and scope of the applications received and the
availability of funds.  Awards will be made for a project period of one year.
All policies and requirements which govern PHS grant programs will apply.
     
Any domestic public or private institution, organization, or association with
one or more research projects supported by the Public Health Service (PHS)
that involves the use of laboratory animals is eligible to apply.  For the
purposes of this program, an institution is defined as the organizational
component covered under a single Biomedical Research Support Grant (BRSG)
code.  Separate applications may be submitted from different colleges or
schools on the same campus of a university within the same fiscal year.
However, a single proposal for a campus-wide program with a single,
centralized animal care program is encouraged whenever possible.
     
The total request for PHS support and the award are limited to $700,000.
Within this limit, the equipment request may be of any size but the A&R
portion cannot exceed $500,000.  Matching funds from non-Federal sources, and
equal to the total award, are required.  These matching funds must be applied
to the specific project described in the application and cannot be met by
citing other expenditures.
     
APPLICATION PROCEDURES
     
There will be a single receipt date of August 6, 1990.  Applications received
after this deadline will be returned without further processing.  Applications
must be submitted on Form PHS 398 (Rev.  10/88).
     
Inquiries about specific instructions for application and other aspects of the
program should be directed to:
     
Animal Resources Program
National Center for Research Resources
National Institutes of Health
Westwood Building, Room 857
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-5175
     
Application forms (PHS 398) may be obtained from grantee business or sponsored
projects offices or from:
     
Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7441
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.306, Laboratory Animal Sciences and Primate Research.  Awards will be made
under the authority of the Public Health Service Act, Title III, Section 301
(Public Law 78.410, as amended; 42 USC 241) and administered under PHS grant
policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74.  This
program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

     
              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 2
MECHANISMS OF VIRAL INDUCED AIDS-ASSOCIATED NEOPLASIA
     
RFA AVAILABLE:  CA-90-15
     
P.T. 34; K.W. 1002045, 0715008, 0715035, 0785140, 0765033, 0755030
     
National Cancer Institute
     
Letter of Intent Receipt Date:  August 17, 1990
Application Receipt Date:  September 18, 1990
     
I. INTRODUCTION
     
Patients infected with the human immunodeficiency virus (HIV), already at high
risk for the development of a broad spectrum of opportunistic infections, are
also at risk for developing a variety of neoplasms.  The number and kind of
such AIDS-associated malignancies are increasing.  While the immunocompromised
status of AIDS patients must play a significant role in the development of
cancer, the possible viral etiology of some of these cancers should also be
considered.  Several mechanisms of oncogenesis involving viruses are possible.
Thus, HIV or one of its genes could cause neoplasia directly; alternatively,
HIV or one of its genes might interact with one of several DNA viruses, such
as cytomegalovirus (CMV) or hepatitis B virus (HBV), etc., with which many
AIDS patients are latently infected, or the HIV-induced immunosuppression may
result in the reactivation of a latent virus, such as Epstein-Barr virus
(EBV), which then may cause B-cell lymphomas directly.  The goal of this
Request for Applications (RFA) is to stimulate research on the mechanisms of
AIDS-associated neoplasias and the role of HIV and other viruses and viral
genes as factors or co-factors in this process.
     
The present RFA is for a single competition with deadlines of September 18,
1990 for receipt of applications and August 17, 1990 for receipt of letters of
intent.
     
II.  RESEARCH GOALS AND SCOPE
     
The major goal of this RFA is to stimulate research on the mechanisms of
AIDS-associated neoplasia in which viruses or viral genes have a role.
Epstein Barr Virus, cytomegalovirus, human papilloma virus, hepatitis B virus
and human T-lymphotropic viruses 1 and 2 are among the suspected oncogenic
viruses having potential for interaction with HIV.  Studies can focus on
oncogenic virus(es) functioning as co-factors in the context of HIV infection
or on HIV serving as a co-factor in the context of oncogenic virus infections.
The areas of proposed investigation include:  1) investigations of the
possibility that the AIDS immunosuppressed state allows for the selection of
virus variants of EBV, CMV, HPV, HBV, HTLV-1, HTLV-2 and HIV which exhibit
differences in virulence, tissue tropism, oncogenic potential, etc.; 2)
investigations of the interactions between viral and cellular genes or viral
and cellular proteins which could be involved in the initiation and
progression of AIDS-associated malignancies; 3) investigations of direct and
indirect processes, such as autocrine and paracrine effects, by which multiple
viral co-infections play a role in AIDS-associated neoplasias; e.g., the
HTLV-1 tax gene transactivates cellular genes, such as IL-2 and GM-CSF, which
could then act upon HIV-infected cells and lead to increased levels of HIV; 4)
the development and use of small animal models to investigate the basis of
virus-induced AIDS-associated neoplasia, e.g. transgenic mice could be used to
study the roles and interaction of various viral genes in the development of
neoplasias; SCID mice reconstituted with components of the human immune system
could be used to investigate the roles of these various components in
immunosurveillance and destruction of virus-transformed cells; and 5)
investigations of the alteration of virus pathogenesis and oncogenesis as a
consequence of the immune status of the patient; e.g., correlates could be
sought between oncogenic viral pathogenesis in AIDS patients with varying
levels of immune function or between AIDS patients and individuals with other
types of immunosuppression such as organ transplant recipients.
     
Where appropriate, collaborative arrangements to facilitate the achievement of
research goals should be considered.
     
Investigators should be aware that NIH urges applicants to give added
attention, where feasible and appropriate, to the inclusion of minorities and
women in study populations.  If minorities and/or women are not included in a
given study, a clear rationale for their exclusion should be provided.
     
III.  MECHANISM OF SUPPORT
     
This RFA will use the National Institutes of Health (NIH) research project
grant (RO1).  Responsibility for the planning, direction and execution of the
     
              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 3
proposed project will be solely that of the applicant.  Except as stated in
this RFA, awards will be administered under PHS grants policy as stated in the
Public Health Service Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.
     
Approximately $1,000,000 in total costs per year for five (5) years will be
committed to specifically fund applications that are submitted in response to
this RFA.  This funding level is dependent on the receipt of a sufficient
number of applications of high scientific merit.  The total project period for
applications submitted in response to the present RFA should not exceed five
(5) years.  The earliest feasible start date will be March 18, 1991.  Although
this program is provided for in the financial plans of the National Cancer
Institute (NCI), award of grants pursuant to this RFA is also contingent upon
the availability of funds for this purpose.  Non-profit and for-profit
institutions are eligible to apply.  Foreign as well as domestic institutions
are eligible.
     
This RFA is a one-time solicitation.  Generally, future unsolicited competing
renewal applications will compete as research project applications with all
other investigator-initiated applications and be reviewed in a standing
Division of Research Grants study section.  However, should the NCI determine
that there is a sufficient continuing program need, NCI may announce a request
for renewal applications.
     
IV.  INQUIRIES
     
Written or telephone inquiries concerning the objectives and scope of this RFA
or inquiries about whether or not specific proposed research would be
responsive are encouraged and should be directed to Dr. Kenneth J. Cremer at
the address below.  The program director welcomes the opportunity to clarify
any issues or questions from potential applicants.
     
Dr. Kenneth J. Cremer
Program Director
AIDS Virus Studies
Biological Carcinogenesis Branch
Division of Cancer Etiology
National Cancer Institute
Executive Plaza North, Room 540
Bethesda, MD  20892
Telephone:  (301) 496-6085

                        ONGOING PROGRAM ANNOUNCEMENTS

SPECIAL EMPHASIS RESEARCH CAREER AWARD:  REHABILITATION AND AGING:  BIOMEDICAL
AND PSYCHOSOCIAL PERSPECTIVES
     
PA:  PA-90-08
     
P.T. 34; K.W. 0710010, 0415003, 0414014, 0710030, 0404000
     
National Institute on Aging
     
The National Institute on Aging (NIA) solicits applications for Special
Emphasis Research Career Awards (SERCA) from eligible institutions for
inter-disciplinary training and research support of individuals seeking
research careers in geriatric rehabilitation.  This SERCA is intended to
foster the career development of investigators with expertise in either:  1)
biomedical, behavioral or social aspects of aging or 2) rehabilitation.  The
main aim of this SERCA is to support the acquisition of skills and experience
in research on rehabilitation of older persons.
     
BACKGROUND
     
Rehabilitation is both a philosophy and a set of techniques aimed at restoring
a person's impaired functioning or to maintain this functioning at the highest
possible level.  Recently, the theories and practices of rehabilitation that
have been developed primarily for younger disabled persons have begun to be
applied to the challenging problems of older people.  A combined medical and
psychosocial approach to restoring, preserving, and enhancing performance and
function in older people is seen as both essential and feasible.
     
The purpose of this SERCA is to encourage research training and research on
the application of rehabilitation technology and approaches toward the chronic
physical and cognitive problems of older individuals.  This announcement is
stimulated by the fact that medical rehabilitation has traditionally
     
              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 4
emphasized the treatment of younger individuals with acute or chronic
disabilities and not the chronic disabilities afflicting many older persons.
There is a clear need for research on rehabilitation interventions targeted at
older persons with a wide range of physical and cognitive disabilities
resulting either from disuse, disorders or injuries of the musculoskeletal,
cardiovascular or other physiological systems.  Further research is needed on
biomedical, social and behavioral aspects of rehabilitation as well as the
combined application of geriatric and psychosocial strategies.
     
A Program Announcement with the same title as this SERCA was released by NIA
last year (NIH Guide, Vol. 18, No. 16, May 5, 1989).  This announcement lists
examples of specific topics of interest to NIA in this area.  This SERCA is
intended to foster the career development of researchers with interests in
these and related topics by encouraging qualified individuals to acquire
in-depth experience and skills in the basic and clinical scientific
disciplines that bear upon this area.
     
PROVISIONS OF THE AWARD
     
This non-renewable award provides support for up to five years of full-time
research and related activities.  The latter may include further development
of research skills.  At least 75 percent of an awardee's time must be spent in
the actual conduct of research.  Supplementation of salary from non-government
sources is allowable.
     
The SERCA grant is made to the awardee's parent institution and provides up to
$40,000 per year for full-time salary support plus fringe benefits.  A maximum
of $10,000 per year during the first three years and up to $20,000 per year
during the remaining two years will be provided for research costs including
technical assistance, equipment, supplies, consultant costs, travel,
publication, and other costs.
     
The grantee institution must be a domestic university, medical school, or
comparable institution with strong, well-established research programs in the
chosen area, adequate numbers of highly trained faculty in clinical and basic
research who will provide guidance in the development of appropriate research
skills.
     
Throughout the grant period, the sponsoring institution is expected to
establish and maintain significant working relationships with the awardee
through an advisor who will sponsor and oversee the proposed program and who
will make sure that the awardee will receive the proper experience for a
future research career in rehabilitation and aging research.
     
The sponsor must be a biomedical, behavioral or social scientist with
extensive research experience and must have a background in rehabilitation or
aging research.
     
The sponsoring institution should facilitate the program by providing space,
resources, and other support insofar as feasible.  While the program should be
situated primarily at a single institution, travel to and stays at other
institutions for relevant research experiences are permissible.
     
ELIGIBILITY REQUIREMENTS
     
Candidates for the SERCA must hold a Ph.D., M.D. or other professional degree
(e.g., D.D.S., D.O., D.V.M., etc.) and by the effective date of the award
should have a minimum of two years of research experience in rehabilitation,
geriatrics, gerontology or other relevant areas.  The award is appropriate for
persons at an early stage of their careers as well as for persons in
mid-career who have worked in other fields and wish to acquire expertise in
rehabilitation research as applied to older persons.  Individuals are not
eligible for this SERCA if they have had previous grant support (exception:
postdoctoral fellowships) in both rehabilitation and aging research.
Applicants with prior grant support in rehabilitation or aging, but not both,
are eligible.  Candidates must be citizens or non-citizen nationals of the
United States or its possessions or territories or must have been lawfully
admitted to the U.S. for permanent residence at the time of application.
Minority and women applicants are encouraged to respond to this announcement.
     
SERCA applications may not be submitted concurrently with other PHS research
career development applications (including all of the K series), which would
duplicate the provisions of the SERCA.  This does not preclude the concurrent
submission of a regular research project grant application.

     

              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 5
MECHANISMS OF SUPPORT
     
The administrative and funding mechanism to be used to support these studies
will be the Special Emphasis Research Career Award (KO1).  The regulations
(Code of Federal Regulations, Title 42, Part 52 and Title 45, Part 74) and
policies that govern the research grant programs of the Public Health Service
will prevail.
     
Applications for this SERCA will compete for funding with applications for
other awards, as no funds have been set aside specifically for funding of
SERCA applications.  Such applications may be submitted for the regular NIH
February 1, June 1, and October 1 receipt deadlines.
     
REVIEW PROCEDURES AND CRITERIA
     
Applications will be received by the NIH Division of Research Grants, assigned
according to referral guidelines, and reviewed in accord with the usual NIH
peer review procedures.  The review criteria are the traditional
considerations underlying scientific merit and career development application.
Following initial review, the applications will be evaluated by the
appropriate National Advisory Council.
     
METHOD OF APPLYING
     
Prospective applicants should obtain the supplemental guidelines for preparing
applications for this SERCA from one of the program officers listed at the end
of this announcement.
     
Applications should be submitted on the standard PHS 398, REV.  10/88,
available at most institutional business offices or from the Division of
Research Grants, NIH, (301) 496-7441.  On item 2 of the face page of the
application, applicants should enter:  "NIA SERCA:  REHABILITATION AND AGING:
BIOMEDICAL AND PSYCHOSOCIAL PERSPECTIVES, PA-90-08".
     
The completed original application and six copies should be sent to:
     
Application Receipt
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Inquires about the SERCA and requests for supplemental guidelines should be
directed to:
     
Richard Weindruch, Ph.D.
Geriatrics Branch
National Institute of Aging
Building 31, Room 5C27
Bethesda, MD  20892
Telephone:  (301) 496-1033
     
Marcia Ory, Ph.D., M.P.H.
Behavioral and Social Research Program
National Institute on Aging
Building 31, Room 5C32
Bethesda, MD  20892
Telephone:  (301) 496-3136
     
Teresa Radebaugh, Sc.D.
Neuroscience and Neuropsychology of Aging Program
National Institute on Aging
Building 31, Room 5C35
Bethesda, MD  20892
Telephone:  (301) 496-9350

     

     

     

     

              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 6
EPIDEMIOLOGIC STUDIES OF CANCER AND HUMAN RETROVIRUSES
     
PA:  PA-90-09
     
P.T. 34; K.W. 0715035, 1002045, 0785055, 0715008
     
National Cancer Institute
     
Application Receipt Dates:  January 2, May 1, September 1
     
I  INTRODUCTION
     
The Division of Cancer Etiology of the National Cancer Institute invites grant
applications for epidemiologic studies of the role of retroviruses, including
human immunodeficiency viruses (HIVs), in the incidence and progression of
malignancies.
     
II BACKGROUND
     
The National Cancer Institute has a continuing interest in the study of
malignancies associated with the human retroviruses, particularly HIVs.  Some
cancers of the lymphoreticular system (non-Hodgkin's lymphoma) and soft tissue
(Kaposi's sarcoma) are significantly increased in incidence and display an
aggressive pattern of development and progression in HIV-infected individuals.
Other tumor types, such as papillomavirus-associated cancers, may also be
emerging more frequently in association with HIV infection.
     
HIV-1 infection is a major health problem in some developing countries, and
the rate of disease progression and the major modes of HIV transmission appear
to be different from those most prominent in the United States.  For example,
as much as 80 percent of HIV infection in Africa is acquired by heterosexual
transmission; in Asian countries, intravenous drug use, prostitution, and
receipt of blood products are major transmission modes.  The route of HIV
infection may be responsible for differences in clinical outcomes, as Kaposi's
sarcoma (KS) is less common in individuals who have acquired infection through
intravenous drug abuse or the administration of blood products compared to
other routes of infection.  It remains to be determined whether the change
from predominantly indolent, endemic KS to the more widespread occurrence of
an aggressive, epidemic form of KS in Africa has resulted from HIV infections,
and whether KS is disproportionately represented as an AIDS-associated illness
in the KS-endemic areas of central Africa compared to non-endemic areas.
While KS is very rare in children with AIDS in the United States, 5-10 percent
of African children with HIV infection have been reported to have KS.  It is
not known whether HIV has had an impact on the incidence of Burkitt's lymphoma
(BL) in Africa, and whether HIV-associated BL in Africa has the same frequency
of specific chromosomal rearrangements as the HIV-unassociated form, as is the
case in the United States.  Comparing etiologic factors for KS, non-Hodgkin's
lymphoma, BL and other tumors in different geographic areas could contribute
to our understanding of retroviral carcinogenesis.
     
Human immunodeficiency virus type 2 (HIV-2) has some characteristics similar
to HIV-1 and has been reported from African, South American and Caribbean
countries but is rare elsewhere.  Some cases of AIDS have been attributed to
HIV-2 infection, but whether this virus is associated with enhanced
development of malignancies is unknown.
     
Infection with another retrovirus, human T-lymphotropic virus 1 (HTLV-1), has
been shown to cause adult T-cell leukemia.  Endemic areas are found in Japan,
the Caribbean area, equatorial Africa, and parts of southeastern United
States.  There is evidence suggesting HTLV-1 may be indirectly associated with
risk of other malignancies, possibly by chronic antigenic stimulation or
alteration of immune function.  Although the cumulative incidence of
malignancy among those infected with HTLV-1 is low, it is still higher than
that for other human oncogenic viruses.  Whether human T-lymphotropic virus 2
(HTLV-2) is associated with an increased risk of malignancies is unknown.
     
III RESEARCH GOALS AND SCOPE
     
The proposed initiative seeks to encourage epidemiologic research projects on
the incidence and etiology of retrovirus-associated malignancies in North
America and Europe, comparative epidemiologic studies of these malignancies in
several geographic areas, or such studies in areas outside of North America or
Europe.  The initiative will permit a wide range of investigations, including,
but not limited to, the following:
     
  o  Investigations of KS (in both the endemic and epidemic forms) and
     non-Hodgkin's lymphoma (including Burkitt's lymphoma) in adults
     and/or children.  Epidemiologic, genetic and multidisciplinary
     
              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 7
     approaches may be used to elucidate the role of HIV and other viral
     and nonviral factors in carcinogenesis;
     
  o  Epidemiologic studies of the role of retroviruses, including the
     HIVs and the HTLVs, in the etiology of human malignancies.
     Historic collections of sera and other biologic materials
     maintained at various locations that can be well characterized
     epidemiologically can be utilized in conducting surveys of virus
     prevalence or in historical cohort studies of the association
     between viral infections, coinfections, and malignancies;
     
  o  Studies monitoring retrovirus-associated malignancies, for example,
     through population-based registries; programs to enhance and
     utilize tumor registries in areas with high prevalence of
     retroviral infection; programs to collect tumor samples and other
     biologic materials from retrovirus-infected and uninfected
     individuals who develop cancer, for utilization by collaborating
     laboratory-based scientists with expertise in elucidating cancer
     etiology.
     
Where feasible and appropriate, applications for the proposed clinical studies
should include a suitable representation of minorities and women.  If the
applicant cannot comply, a clear rationale for their exclusion must be
provided.
     
IV MECHANISM OF SUPPORT
     
This program will be supported through traditional R01 research grants.
Awards will be administered under Public Health Service grants policy as
stated in the PHS Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.  The total project period for applications
submitted in response to the Program Announcement should not exceed five
years.  The present Program Announcement will remain in effect until
retracted.  Future competitive renewal applications of grants funded under
this Program Announcement will compete with all other unsolicited applications
received.
     
V ELIGIBILITY
     
Non-profit and for-profit organizations and institutions, governments and
their agencies, and individuals are eligible to apply.  Foreign as well as
domestic institutions are eligible.
     
VI APPLICATION AND REVIEW PROCEDURES
     
Applications must be submitted on FORM PHS-398, revised 10/88, available in
the business or grants office at most academic or research institutions, or
from the Division of Research Grants, National Institutes of Health, Room 449,
Westwood Building, 5333 Westbard Avenue, Bethesda, Maryland 20892.  The format
and instructions applicable to regular research grant applications should be
followed.  Applications will be accepted in accordance with the date for
receipt of applications on or before January 2, May 1, or September 1 (AIDS
application deadlines).
     
The phrase "IN RESPONSE TO PROGRAM ANNOUNCEMENT -- PA-90-09, RETROVIRUS CANCER
EPIDEMIOLOGY" must be typed on line 2 of the face page of the application, and
YES must be checked.  The completed, signed original and 24 signed, exact
copies should be submitted in one package to the Division of Research Grants
at the address below.  The photocopies must be clear and single-sided.
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892-4500**
     
Applications must be responsive to this Program Announcement.  If an
application is judged by NIH to be unresponsive, it will be reviewed with all
other unsolicited applications received by NIH.
     
The Division of Research Grants will not accept any application in response to
the announcement that is the same as one currently being considered by any
other National Institutes of Health awarding unit.  Applications will be
assigned to the most appropriate regular study section by the Division of
Research Grants.  The second level of review by an appropriate national
advisory board or council will consider the special needs and the priorities
of the National Institutes of Health.  Funding decisions will be based on the
above evaluations and on the availability of funds.

              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 8
Review criteria considered in evaluating applications will be:
     
  o  Scientific merit and originality of research approach, design, and
     methodology;
     
  o  Research experience and competence of the Principal Investigator
     and staff to conduct the proposed studies;
     
  o  Documentation of appropriate collaborative arrangements;
     
  o  Adequacy of time (effort) that the Principal Investigator and staff
     would devote to the proposed studies;
     
  o  Adequacy of essential facilities and resources, or completeness and
     feasibility of the plans for their establishment;
     
  o  Conformity to the Announcement guidelines.
     
The review group will recommend an appropriate budget for each approved
application.
     
VII INQUIRIES
     
Inquiries concerning this announcement should be directed to Dr. G. Iris
Obrams at the address below.
     
G. Iris Obrams, M.D., Ph.D.
Extramural Programs Branch
Epidemiology and Biostatistics Program
Division of Cancer Etiology
National Cancer Institute
Executive Plaza North, Suite 535
Bethesda, MD  20892
Telephone:  (301) 496-9600
     
Investigators with an interest in laboratory and virologic aspects of
AIDS-associated neoplasia may also wish to review the scientific goals of the
National Cancer Institute Request for Applications, number CA-90-15, entitled
"MECHANISMS OF VIRAL-INDUCED AIDS-ASSOCIATED NEOPLASIA, elsewhere in this
issue.
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.393, Cancer Cause and Prevention Research.  Awards will be made under
authorization of the Public Health Service Act, Title III, Section 301(c) and
Section 402 (Public Law 78-410, as amended; 42 USC 241; 42 USC 282) and
administered under PHS grant policies and Federal regulations 42 CFR Part 52
and 45 CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency review.

                                    ERRATA

RESEARCH DEMONSTRATIONS ON EMERGENCY MENTAL HEALTH SERVICES FOR CHILDREN AND
ADOLESCENTS
     
RFA:  MH-90-20
     
P.T. 34, AA; K.W. 0715129, 0730050
     
National Institute for Mental Health
     
In the NIH Guide for Grants and Contracts of March 23, 1990, Vol. 19, No. 12,
Pg. 7, this RFA is incorrectly numbered MH-90-19.
     
The correct number for this RFA is MH-90-20.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
     
5333 Westbard Avenue
Bethesda, Maryland 20816

              NIH GUIDE - Vol. 19, No. 18, May 4, 1990 - Page 9